Lecanemab

Mahesh Narayan, a biophysicist and professor at the University of Texas at El Paso, envisions a day when a truck from a lab might back into a parking spot behind the local Starbucks in service of treating Parkinson’s disease. Recent studies have demonstrated a correlation between drinking coffee and

👉 **TL;DR: This post is just the long—really long—and winding rant of a guy with a dog.** **Avoid reading this and go enjoy your life doing something else instead.** ​ **LCID starts to move.** Today, LCID started to move at 12:20 EST. Twenty-three minutes later, the reason surfaced:

**This is a re-post from my blog.** My first Lecanemab infusion was October 28, 2025. My tenth was February 17, 2026. The most frustrating part of Lecanemab treatment is not knowing if it is helping me. Is Lecanemab slowing the progression of my Alzheimer’s disease? I have no idea, and neither does

I published the following to my blog today: Last week, at the 2026 International Conference on Alzheimer's and Parkinson's Diseases, Eisai presented new real-world findings on the long-term usage of Lecanemab. Analyzing data from the [PurpleLab claims database](https://info.purplelab.com/clear-claim

Can someone convince me that Leqembi is actually a significant advancement in Alzheimer’s treatment? I admit to my ignorance in pharmacology, and I haven’t seen any legitimate articles on the drug. Therefore I’m trying to be very open minded if someone gives me an educated response. To me, Leqembi